WO2004110416A3 - Use of a cx3c agonist for the treatment of pain and for promoting nerve regeneration - Google Patents

Use of a cx3c agonist for the treatment of pain and for promoting nerve regeneration Download PDF

Info

Publication number
WO2004110416A3
WO2004110416A3 PCT/GB2004/002391 GB2004002391W WO2004110416A3 WO 2004110416 A3 WO2004110416 A3 WO 2004110416A3 GB 2004002391 W GB2004002391 W GB 2004002391W WO 2004110416 A3 WO2004110416 A3 WO 2004110416A3
Authority
WO
WIPO (PCT)
Prior art keywords
pain
agonist
treatment
cx3c
nerve regeneration
Prior art date
Application number
PCT/GB2004/002391
Other languages
French (fr)
Other versions
WO2004110416A2 (en
Inventor
David Wynick
Original Assignee
Neurotargets Ltd
David Wynick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurotargets Ltd, David Wynick filed Critical Neurotargets Ltd
Publication of WO2004110416A2 publication Critical patent/WO2004110416A2/en
Publication of WO2004110416A3 publication Critical patent/WO2004110416A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain

Abstract

The invention provides the use of an agonist of a CX3C receptor in the preparation of a medicament for the prevention or treatment of pain and to improve nerve regeneration after nerve in ury or damage. The pain may, for example, be neuropathic pain, inflammatory j pain or pain associated with cancer (other than neuropathic pain), surgery, visceral damage, headache or trauma. The agonist may be fractalkine or a derivative thereof.
PCT/GB2004/002391 2003-06-12 2004-06-04 Use of a cx3c agonist for the treatment of pain and for promoting nerve regeneration WO2004110416A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0313632.2A GB0313632D0 (en) 2003-06-12 2003-06-12 Chemokine receptors
GB0313632.2 2003-06-12

Publications (2)

Publication Number Publication Date
WO2004110416A2 WO2004110416A2 (en) 2004-12-23
WO2004110416A3 true WO2004110416A3 (en) 2005-05-26

Family

ID=27589990

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/002391 WO2004110416A2 (en) 2003-06-12 2004-06-04 Use of a cx3c agonist for the treatment of pain and for promoting nerve regeneration

Country Status (2)

Country Link
GB (1) GB0313632D0 (en)
WO (1) WO2004110416A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20060353A1 (en) * 2006-07-06 2008-01-07 Istituto Neurologico Mediterra USE OF FRACTALCHINA FOR THE PRODUCTION OF A NEUROPROTECTOR DRUG AGAINST CELL DEATH

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076990A1 (en) * 2001-03-27 2002-10-03 Astrazeneca Ab Thiazolopyrimidine derivatives and use thereof as antagonists of the cx3 cr1 receptor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076990A1 (en) * 2001-03-27 2002-10-03 Astrazeneca Ab Thiazolopyrimidine derivatives and use thereof as antagonists of the cx3 cr1 receptor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
COMBADIERE C ET AL: "Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 273, no. 37, 11 September 1998 (1998-09-11), pages 23799 - 23804, XP002158116, ISSN: 0021-9258 *
MILLIGAN E D ET AL: "Evidence that exogenous and endogenous fractalkine can induce spinal nociceptive facilitation in rats.", THE EUROPEAN JOURNAL OF NEUROSCIENCE. NOV 2004, vol. 20, no. 9, November 2004 (2004-11-01), pages 2294 - 2302, XP002321418, ISSN: 0953-816X *
VERGE GAIL M ET AL: "Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions.", THE EUROPEAN JOURNAL OF NEUROSCIENCE. SEP 2004, vol. 20, no. 5, September 2004 (2004-09-01), pages 1150 - 1160, XP002321417, ISSN: 0953-816X *
WATKINS L R ET AL: "Glial activation: a driving force for pathological pain", TRENDS IN NEUROSCIENCE, ELSEVIER, AMSTERDAM, NL, vol. 24, no. 8, 1 August 2001 (2001-08-01), pages 450 - 455, XP004273765, ISSN: 0166-2236 *
WIESELER-FRANK JULIE ET AL: "Glial activation and pathological pain.", NEUROCHEMISTRY INTERNATIONAL. 2004 JUL-AUG, vol. 45, no. 2-3, July 2004 (2004-07-01), pages 389 - 395, XP002321419, ISSN: 0197-0186 *

Also Published As

Publication number Publication date
WO2004110416A2 (en) 2004-12-23
GB0313632D0 (en) 2003-07-16

Similar Documents

Publication Publication Date Title
WO2005102338A8 (en) Method of treating neuropathic pain using a crth2 receptor antagonist
AU2003300095A1 (en) Systems and methods for internal tissue penetration
EP1715893B8 (en) Direct compression formulation and process
WO2007021657A3 (en) Orthopaedic fixation clamp and method
WO2007002927A3 (en) Imaging geometry
AU2003902503A0 (en) Medical Apparatus, Use and Methods
TW200505881A (en) Tri(cyclo) substituted amide compounds
EP1797281A4 (en) Method of estimating fracture geometry, compositions and articles used for the same
IL185983A0 (en) Active compression orthopedic plate system and method for using the same
WO2007070052A3 (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
EP2450041A3 (en) Improved testosterone gel and method of use
WO2006124587A3 (en) Device for stabilizing an arm
WO2005123116A3 (en) Compositions and methods for treating or preventing oxalate-related disease
WO2003061593A3 (en) Novel targeted compositions for diagnostic and therapeutic use
WO2004073623A3 (en) Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
WO2006023704A3 (en) Lonidamine analogues and their use in male contraception and cancer treatment
WO2004091540A3 (en) Methods of treating pain and compositions for use therefor
WO2003090696A3 (en) Methods and products for mucosal delivery
EP2030615A3 (en) Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
ZA200808465B (en) Pharmaceutical formulations:salts of 8-[{1-(3,5-bis (trifluoromethy1)pheny1)-e thoxy}-methy1]-8-pheny1-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
WO2004103283A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage
WO2007079312A3 (en) Compositions and methods for treating actin-mediated medical conditions
WO2007006732A8 (en) Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist)
TWI372047B (en) Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same
WO2005000192A3 (en) Glycogen synthase kinase-3 inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase